MIIP (migration and invasion inhibitory protein) functions as a tumor suppressor that inhibits cell migration, invasion, and proliferation across multiple cancer types. Located on chromosome 1.22, a frequently deleted region in cancers, MIIP exerts its primary effects through interaction with IGFBP2, antagonizing its pro-migratory functions 1. Mechanistically, MIIP regulates the cytoskeleton by inhibiting HDAC6, a histone deacetylase that deacetylates α-tubulin, leading to increased microtubule acetylation and stabilization 23. MIIP also modulates the mitotic checkpoint, delaying mitosis and suppressing tumorigenesis 2. Additionally, MIIP negatively regulates AKT signaling in hepatocellular carcinoma 4. Disease relevance is substantial: MIIP expression is significantly downregulated in breast cancer 15, nasopharyngeal carcinoma, choriocarcinoma, and hepatocellular carcinoma. Loss of heterozygosity at the MIIP locus correlates with advanced clinical stage, larger tumors, and shorter survival in breast cancer patients 5. Therapeutically, MIIP upregulation or restoration inhibits tumor growth and metastasis, while MIIP-enhanced cells demonstrate increased radiosensitivity to ionizing radiation 6, suggesting potential combinatorial treatment strategies for refractory malignancies.